Sun Pharma Rating ‘buy’: Q3 results were in line with expectations

By: |
February 11, 2020 1:30 AM

India revenue growth of 13% key positive; adjusting for Q3 and lower Taro sales, FY20/21/22e EPS down 4/7/1%; ‘Buy’ maintained

SUNP reported results that were in line with expectations, with profit after tax 4% below expectations due to higher taxes and depreciation.

SUNP reported Q3FY20 results in line with expectations, with revenues 2% below but margins 138bp ahead of expectations. India revenues grew 13% and were the key positive. US business ex Taro was in line. Specialty revenues was up 30% q-o-q led by seasonality and Cequa. We remain positive on the outlook for the specialty business, for which our doc survey suggests $300-mn Ilumya peak sales. With valuations at 15x FY22 PE (15% disc. to peers), we maintain Buy.

In-line quarter: SUNP reported results that were in line with expectations, with profit after tax 4% below expectations due to higher taxes and depreciation.

India strong; US in-line: India revenues were 2% ahead of expectations. US revenues, at $350 mn, were 3% below expectations led entirely by Taro which declined 16% y-o-y. US ex Taro revenues were up 11% q-o-q led by specialty business. RoW revenues were in line with expectation. EM revenues declined 5% due to lower tender sales ex of which revenues were up 15% y-o-y.

 

Margins: Margins were 138bp ahead of expectations, led by lower R&D. Taro margins were up 40bps q-o-q.

Conf call highlights: Mgmt indicated that FY20 R&D will be lower than 8-9% guidance but R&D will be higher in FY21. It is increasing its India sales force by c10%. This will be on board by Q1FY21. Cequa is evaluating DTC promotion.

Estimates: We adjust our estimates for the quarter and lower Taro sales. We increase FY21/22 R&D to 8% vs 7% earlier. We change our USD/INR to 70.5/ 72/72 vs 70.23/71.06/72 for FY20/ 21/22. Our FY20/21/22 EPS changes by -4/-7/-1%.

Remain positive on Specialty: Ilumya’s ramp-up has been slow, but we remain positive on both Ilumya and Cequa. Our doctor survey in the US highlighted that Ilumya could achieve peak sales of $300 mn. The ramp-up, though, is set to be slow, occurring over the next 12m. Cequa has seen a strong ramp-up in 3m since launch, is at c$15 mn annualised run-rate and we expect it to reach $100 mn+ peak sales.

Risk-reward favourable: Sun is trading at 15.4x FY22 PE, a 15% discount to peers. Risk-reward is favourable, in our view. We expect the base business to recover steadily. We expect the Specialty business to turn Ebitda positive in FY22 from a $150-mn Ebitda loss currently. Maintain Buy with Rs 520 TP, valuing it at 18.5x FY22 base PE.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1ICICI Lombard rating – Buy: Higher commissions impacted earnings
2Gateway Distriparks rating – Buy: Results came as a positive surprise
3NTPC to raise Rs 2,500 cr via bonds on Wednesday